Trial · NCT01521715
First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
NCT01521715, Phase 4, Completed, iOMEDICO AG
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma. Trials, record NCT01521715. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01521715
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- First Line Pazopanib in Poor Risk Patients With Metastatic Renal Cell Carcinoma
- NCT number
- NCT01521715
- Status
- Completed
- Phases
- Phase 4
- Enrollment
- 44 participants, actual
- Lead sponsor
- iOMEDICO AG
- Conditions
- Locally Advanced and/or Metastatic Renal Cell Carcinoma, Carcinoma, Renal Cell, Clear-cell Metastatic Renal Cell Carcinoma
- Interventions
- Pazopanib
- First posted
- 2012-01-31
- Last updated
- 2017-08-23
- Other registries' IDs
- eudract:2011-001138-40
Source ClinicalTrials.gov
Registered outcomes6
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Rate of poor risk patients as defined by the Memorial Sloan-Kettering Cancer Center (MSKCC) criteria who are free of disease progression at 6 months after start of first line treatment with pazopanib. | from registration until progression of disease or death, assessed up to 6 months | |
| Secondary | Overall survival of poor risk patients treated with pazopanib. | from registration until death of any cause assessed up 24 months | |
| Secondary | Number, characteristics and severity of Adverse Events | from first dose of pazopanib until 30 days after last dose, death or end of study, whichever came first | |
| Secondary | Progression free survival of patients treated with pazopanib | From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months | |
| Secondary | Overall response rate and duration of response according to Response Evaluation Criteria In Solid Tumors (RECIST) 1.1 | From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months | |
| Secondary | Relation between biomarkers and clinical outcome (response, stable disease, progression of disease) | From date of registration until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 20 months |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01521715
GET https://conductscience.org/api/trials/v1/NCT01521715/registered